The deal tape
A precedent transactions set answers one question: what did somebody actually pay for a company like this one. Every row here is a US public target that filed a merger proxy or a going-private statement since 2020, with the offer per share, the premium to the unaffected price and the enterprise value multiples read from the filing itself rather than bought from a feed. Choose a sector, an industry code and a size band, and the quartiles above the list are the answer for that cut.
What it is not. Private-company deals, non-US targets and any transaction where no proxy was required leave nothing to read, so none of them are here. Neither are minority stakes or asset sales. Where a cross-check failed, the row still appears and says why, and it is held out of every median and quartile so one bad reading cannot move a number you would quote.
104 deals in this cut, 50 of them safe to take a multiple from and 99 safe to take a premium from. Enterprise value is stated where a balance sheet and a share count could be read at the period end before announcement.
What this cut was bought at
Each measure counts the readings that survive its own cross-checks. Fewer than 4 is a coincidence, not a market.
| Measure | Deals | 25th | Median | 75th |
|---|---|---|---|---|
| EV / LTM EBITDA | 19 | 12.0x | 17.8x | 26.6x |
| EV / LTM revenue | 43 | 0.9x | 2.0x | 4.4x |
| Premium to unaffected price | 58 | 22% | 40% | 58% |
| Premium to 30-day VWAP | 15 | 23% | 32% | 45% |
Read the EBITDA multiple against the revenue multiple before you use either. Where they disagree sharply the target was priced on growth rather than earnings, and the EBITDA line is the one that will not survive a second question.
| Target | Acquirer | Industry | EV | EV / EBITDA | EV / revenue | Premium | Filing |
|---|---|---|---|---|---|---|---|
SpringWorks Therapeutics, Inc. 2025-04-27 · Public merger · $47.00 a share | Merck KGaA Strategic | Healthcare | $3.5bn | n.a. | 17.3x | 17% | DEFM14A All cash |
HarborOne Bancorp, Inc. 2025-04-24 · Public merger · $12.00 a share Held out of the multiples: consideration includes stock: the cash figure is not the price | Eastern Bankshares, Inc. Strategic | Financials | $846m | n.a. | n.a. | n.a. | DEFM14A Includes stock |
Icad Inc 2025-04-15 · Public merger · $3.61 a share Held out of the multiples: consideration includes stock: the cash figure is not the price | RadNet, Inc. Strategic | Healthcare | $79m | n.a. | 4.0x | 98% | DEFM14A Includes stock |
Old Point Financial Corp 2025-04-02 · Public merger · $41.00 a share Held out of the multiples: consideration includes stock: the cash figure is not the price | The Old Point National Bank of Phoebus Strategic | Financials | $77m | n.a. | 0.9x | n.a. | DEFM14A Includes stock |
Dada Nexus Ltd 2025-04-01 · Take-private · $2.00 a share Held out of the multiples: consideration includes stock: the cash figure is not the price Board book on file → | JD Sunflower Investment LTD Strategic | Technology | $1.7bn | n.a. | 1.3x | 42% | SC 13E3 Includes stock |
Rocket Companies, Inc. 2025-03-31 · Public merger · $2.00 a share Held out of the multiples: consideration includes stock: the cash figure is not the price | Redfin Corporation Strategic | Financials | $2.3bn | n.a. | n.a. | 39% | DEFM14C Includes stock |
Maverick Merger Sub 2, LLC 2025-03-31 · Public merger · $2.00 a share Held out of the multiples: consideration includes stock: the cash figure is not the price | Rocket Companies, Inc. Strategic | Financials | -$657m | n.a. | -0.3x | 39% | DEFM14A Includes stock |
LENSAR, Inc. 2025-03-23 · Public merger · $14.00 a share | Alcon Research, LLC Strategic | Healthcare | $143m | n.a. | 3.1x | 18% 24% to VWAP | DEFM14A All cash |
AZEK Co Inc. 2025-03-23 · Public merger · $26.45 a share Held out of the multiples: consideration includes stock: the cash figure is not the price | James Hardie Industries plc Strategic | Materials | $4.4bn | 12.4x | 3.0x | 14% | DEFM14A Includes stock |
Dun & Bradstreet Holdings, Inc. 2025-03-23 · Public merger · $9.15 a share Held out of the multiples: consideration includes stock: the cash figure is not the price | Denali Intermediate Holdings, Inc. Strategic | Technology | $7.4bn | 9.5x | 3.1x | 8% | DEFM14A Includes stock |
Proassurance Corp 2025-03-19 · Public merger · $25.00 a share | The Doctors Company Strategic | Financials | $1.6bn | n.a. | 1.4x | 59% | DEFM14A All cash |
OptiNose, Inc. 2025-03-19 · Public merger · $9.00 a share | Paratek, Inc. Strategic | Healthcare | $133m | n.a. | 1.7x | 50% | DEFM14A All cash |
Radius Recycling, Inc. 2025-03-13 · Public merger · $30.00 a share | Toyota Tsusho America, Inc. Strategic | Industrials | $431m | n.a. | 0.2x | 115% | DEFM14A All cash |
Checkpoint Therapeutics, Inc. 2025-03-09 · Public merger · $4.10 a share | Sun Pharmaceutical Industries, Inc. Strategic | Healthcare | $213m | n.a. | n.a. | 66% 32% to VWAP | DEFM14A All cash |
Nevro Corp 2025-02-06 · Public merger · $5.85 a share | Globus Medical, Inc. Strategic | Healthcare | $152m | n.a. | 0.4x | 14% | DEFM14A All cash |
ACELYRIN, Inc. 2025-02-06 · Public merger · $1.00 a share Held out of the multiples: consideration includes stock: the cash figure is not the price | Alumis Inc. Strategic | Healthcare | $26m | n.a. | n.a. | 57% | DEFM14A Includes stock |
Whitehawk Therapeutics, Inc. 2025-01-31 (filed) · Public merger · $2.40 a share | Private Aadi Strategic | Healthcare | $75m | n.a. | 5.0x | n.a. | DEFM14A All cash |
Paragon 28, Inc. 2025-01-28 · Public merger · $13.00 a share | Zimmer, Inc., Inc. Strategic | Healthcare | $1.2bn | n.a. | 4.5x | 96% | DEFM14A All cash |
Logility Supply Chain Solutions, Inc 2025-01-24 · Public merger · $14.30 a share | Aptean, Inc. Strategic | Technology | $397m | 43.2x | 3.9x | 26% | DEFM14A All cash |
Redwire Corp 2025-01-20 · Public merger · $1.00 a share Held out of the multiples: consideration includes stock: the cash figure is not the price | Edge Autonomy Ultimate Holdings, LP Strategic | Industrials | $159m | n.a. | 0.5x | n.a. | DEFM14A Includes stock |
Techpoint, Inc. 2025-01-15 · Public merger · $20.00 a share Held out of the premiums: premium of 171%: distressed or misread | ASMedia Technology Inc. Strategic | Technology | $300m | 15.4x | 4.2x | 171% | DEFM14A All cash |
Enfusion, Inc. 2025-01-10 · Public merger · $10.50 a share Held out of the multiples: consideration includes stock: the cash figure is not the price | Clearwater Analytics Holdings, Inc. Strategic | Technology | $305m | 17.0x | 1.5x | n.a. | DEFM14A Includes stock |
Intra-Cellular Therapies, Inc. 2025-01-10 · Public merger · $132.00 a share | Johnson & Johnson Strategic | Healthcare | $13bn | n.a. | 19.1x | 60% 50% to VWAP | DEFM14A All cash |
ESSA Bancorp, Inc. 2025-01-09 · Public merger · $21.00 a share Held out of the multiples: consideration includes stock: the cash figure is not the price | CNB Bank Strategic | Financials | $543m | n.a. | n.a. | n.a. | DEFM14A Includes stock |
Akoya Biosciences, Inc. 2025-01-09 · Public merger · $0.38 a share Held out of the multiples: consideration includes stock: the cash figure is not the price | Stock Consideration, Inc. Strategic | Industrials | $60m | n.a. | 0.7x | 24% | DEFM14A Includes stock |
How to use a set like this
Cut to the narrowest set that still holds eight or ten deals, then quote the range rather than the median. An interviewer who asks where software takes out will accept a spread and press on a single number, because the single number implies a precision the set does not have. Say which deals sit at each end and why: the top of a range is usually a contested auction or a strategic buyer with synergies, the bottom a controlling holder buying in the minority.
Premiums move with the reference price, not only with the deal. A bidder quotes the period that flatters the offer, so read the premium to the unaffected close beside the premium to the thirty-day average and notice when they diverge.
What each column means
- Enterprise value.
- Offer per share times shares outstanding, plus net debt at the last balance sheet before the merger agreement. It is blank where either piece was missing, and those rows are in the “not computed” band rather than in a size they never earned.
- Premium.
- The offer against the unaffected price, which is the last close before the deal became known. Where the filing states a premium to the thirty-day volume-weighted average, that is shown next to it.
- Deal type.
- A take-private is bought by an affiliate, which is what triggers the Schedule 13E-3 and the fuller disclosure that comes with it. A public merger is an arm’s-length buyer, disclosed through the merger proxy.
- In doubt.
- A cross-check the reading could not satisfy: an equity value far from the fee-table figure, a multiple outside any sane band, or consideration that is partly stock so the per-share cash figure is not the price. The row stays visible, and it is set aside only for the measures the doubt reaches. A cash-and-stock deal cannot price a multiple and still states a premium the filing itself computed, so it counts in one and not the other.
Company names, tickers and logos are the trademarks of their respective owners and appear here to identify the company whose public figures are being used. L3VLUP is not affiliated with, sponsored by or endorsed by any company shown, and nothing here is a statement by or about that company. More